All In Biotech

Drug Trial Radar · NCT06645886

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KQB198 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hematologic Malignancies

Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

13

Actual

Start

Dec 9, 2024

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Kumquat Biosciences Inc.Industry
Sponsor type
Industry
First posted
Oct 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that

Conditions

  • Hematologic Malignancies
  • Adult

Interventions

  • KQB198Drug

    Oral KQB198

  • DasatinibDrug

    Oral dasatinib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities (Part 1)Time frame: 28 Days
  2. Recommended Phase 2 Dose (RP2D) (Part 1)Time frame: Up to 30 months
  3. Efficacy of study treatment and optimal biologic dose, as measured by molecular response (MR) per European Leukemia Network (ELN) 2020 Guidelines (Part 2).Time frame: Up to 6 Months

Locations

29 sites in 8 countries. Site status is shown where the registry gives one.

  • University of California, San Francisco (UCSF)

    San Francisco, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Moffitt Cancer Center

    Tampa, Florida

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Duke University Medical Center

    Durham, North Carolina

  • Oncology Hematology Cincinnati

    Cincinnati, Ohio

  • Sarah Cannon Research Institute (SCRI) - Transplant and Cellular Therapy Operations

    Nashville, Tennessee

  • Texas Oncology Austin Central

    Austin, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • AP-HM - Hopital de la Timone

    Marseille, France

  • CHRU de Tours - Hopital Bretonneau

    Tours, Centre-Val de Loire, France

  • Medizinische Hochschule Hannover (MHH)

    Hanover, Lower Saxony, Germany

  • Universitaetsklinikum Jena

    Jena, Thuringia, Germany

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola

    Bologna, Bologna, Italy

  • Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

    Rome, Lazio, Italy

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Lombardy, Italy

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano

    Milan, Milan, Lombardy, Italy

  • Stichting Radboud Universitair Medisch Centrum

    Nijmegen, Gelderland, Netherlands

  • Aidport Sp. z o.o.

    Poznan, Greater Poland Voivodeship, Poland

  • Copernicus PL Sp. z o.o., Wojewodzkie Centrum Onkologii

    Gdansk, Pomeranian Voivodeship, Poland

  • Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii

    Gdansk, Pomeranian Voivodeship, Poland

  • Pratia Onkologia Katowice

    Katowice, Silesian Voivodeship, Poland

  • Hospital Regional Universitario de Malaga

    Málaga, Andalusia, Spain

  • Institut Catala d'Oncologia - L'Hospitalet

    L'Hospitalet de Llobregat, Catalonia, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Madrid, Spain

  • Hammersmith Hospital

    London, Greater London, United Kingdom

  • Nottingham University Hospitals

    Nottingham, Nottinghamshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.